vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与Vivid Seats Inc.（SEAT）财务数据对比。点击上方公司名可切换其他公司
Vivid Seats Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.3倍（$97.5M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -41.0%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-38.3M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -21.9%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Vivid Seats Inc.是一家美国在线票务交易与转售企业，目前是ESPN、联合航空、旧金山49人队、洛杉矶闪电队等多家体育队伍与媒体机构的官方票务合作伙伴，还推出了会员奖励计划，消费者购票可累计积分，同时该公司也是倡导网络中立性的互联网协会成员。
PBYI vs SEAT — 直观对比
营收规模更大
SEAT
是对方的1.3倍
$75.5M
营收增速更快
PBYI
高出68.7%
-41.0%
自由现金流更多
PBYI
多$52.7M
$-38.3M
两年增速更快
PBYI
近两年复合增速
-21.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $97.5M |
| 净利润 | — | $1.2B |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | — |
| 净利率 | — | 1212.8% |
| 营收同比 | 27.7% | -41.0% |
| 净利润同比 | — | 12369.2% |
| 每股收益（稀释后） | $0.26 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYISEAT
| Q4 25 | $75.5M | $97.5M | ||
| Q3 25 | $54.5M | $104.8M | ||
| Q2 25 | $52.4M | $114.5M | ||
| Q1 25 | $46.0M | $133.7M | ||
| Q4 24 | $59.1M | $165.2M | ||
| Q3 24 | $80.5M | $152.7M | ||
| Q2 24 | $47.1M | $170.0M | ||
| Q1 24 | $43.8M | $160.0M |
净利润PBYISEAT
| Q4 25 | — | $1.2B | ||
| Q3 25 | $8.8M | $-30.2M | ||
| Q2 25 | $5.9M | $-335.4M | ||
| Q1 25 | $3.0M | $-10.6M | ||
| Q4 24 | — | $-9.6M | ||
| Q3 24 | $20.3M | $10.6M | ||
| Q2 24 | $-4.5M | $-437.0K | ||
| Q1 24 | $-4.8M | $12.9M |
毛利率PBYISEAT
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYISEAT
| Q4 25 | 22.7% | — | ||
| Q3 25 | 17.6% | — | ||
| Q2 25 | 12.7% | — | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 27.4% | — | ||
| Q2 24 | -4.6% | — | ||
| Q1 24 | -5.3% | — |
净利率PBYISEAT
| Q4 25 | — | 1212.8% | ||
| Q3 25 | 16.2% | -28.9% | ||
| Q2 25 | 11.2% | -293.0% | ||
| Q1 25 | 6.5% | -7.9% | ||
| Q4 24 | — | -5.8% | ||
| Q3 24 | 25.2% | 7.0% | ||
| Q2 24 | -9.6% | -0.3% | ||
| Q1 24 | -11.0% | 8.0% |
每股收益（稀释后）PBYISEAT
| Q4 25 | $0.26 | — | ||
| Q3 25 | $0.17 | — | ||
| Q2 25 | $0.12 | — | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $0.41 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.10 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $102.7M |
| 总债务越低越好 | $22.7M | $16.5M |
| 股东权益账面价值 | $130.3M | $-85.1M |
| 总资产 | $216.3M | $636.9M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYISEAT
| Q4 25 | $97.5M | $102.7M | ||
| Q3 25 | $94.4M | $145.1M | ||
| Q2 25 | $96.0M | $153.0M | ||
| Q1 25 | $93.2M | $199.5M | ||
| Q4 24 | $101.0M | $243.5M | ||
| Q3 24 | $96.7M | $202.3M | ||
| Q2 24 | $96.8M | $234.3M | ||
| Q1 24 | $107.2M | $154.0M |
总债务PBYISEAT
| Q4 25 | $22.7M | $16.5M | ||
| Q3 25 | $34.0M | $17.1M | ||
| Q2 25 | $45.3M | $17.7M | ||
| Q1 25 | $56.7M | $18.2M | ||
| Q4 24 | $68.0M | $18.7M | ||
| Q3 24 | $79.3M | $15.8M | ||
| Q2 24 | $90.7M | $16.1M | ||
| Q1 24 | $102.0M | $15.7M |
股东权益PBYISEAT
| Q4 25 | $130.3M | $-85.1M | ||
| Q3 25 | $115.3M | $272.2M | ||
| Q2 25 | $104.7M | $217.3M | ||
| Q1 25 | $97.1M | $380.7M | ||
| Q4 24 | $92.1M | $261.1M | ||
| Q3 24 | $71.1M | $329.4M | ||
| Q2 24 | $48.5M | $155.8M | ||
| Q1 24 | $51.0M | $139.6M |
总资产PBYISEAT
| Q4 25 | $216.3M | $636.9M | ||
| Q3 25 | $202.9M | $1.1B | ||
| Q2 25 | $194.9M | $1.1B | ||
| Q1 25 | $196.2M | $1.6B | ||
| Q4 24 | $213.3M | $1.6B | ||
| Q3 24 | $220.7M | $1.6B | ||
| Q2 24 | $205.0M | $1.7B | ||
| Q1 24 | $214.1M | $1.6B |
负债/权益比PBYISEAT
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | 0.06× | ||
| Q2 25 | 0.43× | 0.08× | ||
| Q1 25 | 0.58× | 0.05× | ||
| Q4 24 | 0.74× | 0.07× | ||
| Q3 24 | 1.12× | 0.05× | ||
| Q2 24 | 1.87× | 0.10× | ||
| Q1 24 | 2.00× | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $-38.2M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $-38.3M |
| 自由现金流率自由现金流/营收 | 19.1% | -39.3% |
| 资本支出强度资本支出/营收 | 0.0% | 0.1% |
| 现金转化率经营现金流/净利润 | — | -0.03× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $-93.8M |
8季度趋势，按日历期对齐
经营现金流PBYISEAT
| Q4 25 | $14.4M | $-38.2M | ||
| Q3 25 | $9.7M | $512.0K | ||
| Q2 25 | $14.1M | $-28.6M | ||
| Q1 25 | $3.6M | $-25.3M | ||
| Q4 24 | $15.6M | $47.8M | ||
| Q3 24 | $11.0M | $-19.2M | ||
| Q2 24 | $1.0M | $-13.8M | ||
| Q1 24 | $11.2M | $39.2M |
自由现金流PBYISEAT
| Q4 25 | $14.4M | $-38.3M | ||
| Q3 25 | $9.7M | $502.0K | ||
| Q2 25 | $14.1M | $-28.8M | ||
| Q1 25 | $3.6M | $-27.1M | ||
| Q4 24 | $15.6M | $44.3M | ||
| Q3 24 | $11.0M | $-19.6M | ||
| Q2 24 | $1.0M | $-14.1M | ||
| Q1 24 | — | $39.1M |
自由现金流率PBYISEAT
| Q4 25 | 19.1% | -39.3% | ||
| Q3 25 | 17.7% | 0.5% | ||
| Q2 25 | 26.8% | -25.2% | ||
| Q1 25 | 7.7% | -20.3% | ||
| Q4 24 | 26.4% | 26.8% | ||
| Q3 24 | 13.7% | -12.8% | ||
| Q2 24 | 2.1% | -8.3% | ||
| Q1 24 | — | 24.4% |
资本支出强度PBYISEAT
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.1% | 1.4% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.0% | 0.1% |
现金转化率PBYISEAT
| Q4 25 | — | -0.03× | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | -1.81× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
SEAT
| Concerts | $34.3M | 35% |
| Resale | $29.3M | 30% |
| Theater | $24.4M | 25% |
| Private Label | $7.2M | 7% |
| Other | $2.2M | 2% |
